Press Release
New medicinal cannabis company Kindred by Medigrowth has launched with a crowdfunding campaign aimed to redefine veterinary care with medicinal cannabis. CBD medication trials in dogs found that 83% of dogs showed a decrease in stress or anxiety-related behaviours during a stressful event. As part of Medigrowth’s expanding vision, Kindred aims to support veterinarians with the tools, resources, and education to improve pet health with premium supplements and medicinal cannabis by prescription.
Born from Medigrowth’s success in human medicinal cannabis, Kindred combines clinical expertise with a deep commitment to animal welfare. The company’s launch introduces a comprehensive range of veterinary products, supported by an innovative clinical education platform for veterinarians and evidence-based resources for pet owners.
Kindred’s mission is to improve pets’ health and wellness by providing the highest-quality medicinal cannabis products. To ensure consistency and reliability, Kindred’s products undergo rigorous quality control, including independent testing and strict compounding protocols. The company has also established a dedicated clinical platform that offers veterinarians access to current research and educational resources, empowering them with the knowledge to incorporate this natural therapy into their practice.
“We recognised that animals, like humans, can benefit significantly from medicinal cannabis, particularly for conditions such as anxiety, chronic pain, and osteoarthritis. Our mission is to improve pet health outcomes while empowering veterinarians with the knowledge and tools to incorporate these natural therapies into their practice. The launch also comes at a pivotal time, allowing Australians to invest in the future of plant medicine for pets,” stated Adam Guskich, Founder & CEO of Medigrowth.
With the plant-based medicine market expected to reach $127B by 2028, Medigrowth has hit several major milestones to ensure they are part of this growth. This includes being fully licensed by the Australian Federal Office of Drug Control, secured supply and distribution agreements with significant players in the industry, and a valuable research collaboration with Deakin University to assist with clinical trials and the development of new and novel products. Now is the ideal time to invest in Medigrowth, with expressions of interest open now, see here for more details.
In alignment with their commitment to Australian domestic animal welfare, Kindred supports the RSPCA, pledging one dollar from every prescription processed to support animal protection services nationwide. This initiative reflects the company’s broader mission to make a positive impact beyond commercial operations.
Those so inclined can also invest in the power of plant medicine. Medigrowth’s crowdfunding campaign on Birchal opened for Expressions of Interest on February 4, 2025.
For more information, visit the Kindred website: https://www.kindredcbd.com.au/
